Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis

Arthritis Care and Research

Volumn 63, Issue 7, 2011, Pages 1055-1061

  Walsh, Michael ^a   Mukhtyar, Chetan ^b   Mahr, Alfred ^c   Herlyn, Karen ^d   Luqmani, Raashid ^e   Merkel, Peter A ^f   Jayne, David R W ^g  

^a MCMASTER UNIVERSITY   (Canada)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c University Paris 5 René Descartes ^*  (France)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f BOSTON UNIVERSITY   (United States)

^g ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; METHOTREXATE; METHYLPREDNISOLONE;

ABDOMINAL DISEASE; AGE; ANCA ASSOCIATED VASCULITIS; ARTICLE; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEART DISEASE; HUMAN; KIDNEY DISEASE; MAINTENANCE THERAPY; MENTAL COMPOSITE SCORE; META ANALYSIS; MUCOSA; NEUROLOGIC DISEASE; PHYSICAL COMPOSITE SCORE; PLASMAPHERESIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SHORT FORM 36; SKIN DISEASE; STEROID THERAPY; THORAX DISEASE;

ADULT; AGE FACTORS; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SELF REPORT;

EID: 79959979797     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20471     Document Type: Article

References (25)

1. Bosch X, Guilabert A, Espinosa G, Mirapeix E. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA 2007;298:655-69. (Pubitemid 47236417)
2. Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism Systemic Vasculitis Task Force. Ann Rheum Dis 2008;67:1004-10. (Pubitemid 351956664)
3. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item Short-Form Health Survey (SF-36). II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
4. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
5. Koutantji M, Harrold E, Lane SE, Pearce S, Watts RA, Scott DG. Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum 2003;49:826-37. (Pubitemid 37523636)
6. Newall C, Schinke S, Savage CO, Hill S, Harper L. Impairment of lung function, health status and functional capacity in patients with ANCA-associated vasculitis. Rheumatology (Oxford) 2005;44:623-8. (Pubitemid 41487231)
7. Srouji IA, Andrews P, Edwards C, Lund VJ. General and rhinosinusitis-related quality of life in patients with Wegener's granulomatosis. Laryngoscope 2006;116:1621-5. (Pubitemid 44368083)
8. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44. (Pubitemid 36765101)
9. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9. (Pubitemid 41117433)
10. De Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
11. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007;18:2180-8. (Pubitemid 47041083)
12. Bowling A, Bond M, Jenkinson C, Lamping DL. Short Form 36 (SF-36) Health Survey questionnaire: which normative data should be used? Comparisons between the norms provided by the Omnibus Survey in Britain, the Health Survey for England and the Oxford Healthy Life Survey. J Public Health Med 1999;21:255-70. (Pubitemid 29446064)
13. Jenkinson C, Wright L, Coulter A. Criterion validity and reliability of the SF-36 in a population sample. Qual Life Res 1994;3:7-12. (Pubitemid 24062654)
14. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-92.
15. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-8. (Pubitemid 24334817)
16. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-54. (Pubitemid 46768608)
17. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92. (Pubitemid 24065492)
18. Carlin JB, Galati JC, Royston P. A new framework for managing and analyzing multiply imputed data in Stata. Stata J 2008;8:49-67.
19. Royston P. Multiple imputation of missing values: update. Stata J 2005;5:1-14.
20. Carpenter DM, Thorpe CT, Lewis M, DeVellis RF, Hogan SL. Health-related quality of life for patients with vasculitis and their spouses. Arthritis Rheum 2009;61:259-65.
21. Basu N, Jones GT, Fluck N, MacDonald AG, Pang D, Dospinescu P, et al. Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis. Rheumatology (Oxford) 2010;49:1383-90.
22. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gutfleisch J, Peter HH, Raspe HH, et al. Effect of Wegener's granulomatosis on work disability, need for medical care, and quality of life in patients younger than 40 years at diagnosis. Arthritis Rheum 2002;47:320-5. (Pubitemid 34627701)
23. Exley AR, Carruthers D, Kitas G, Luqmani RA, Bacon P. Functional outcome vs damage in systemic vasculitis [abstract]. Arthritis Rheum 1996;39 Suppl: S66.
24. Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005;52:2168-78. (Pubitemid 40994340)
25. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118:622-9. (Pubitemid 23102698)